” The best way to predict the future is to create it “
(Peter Drucker – Professor, author & theoretician)

At macopharma, we believe in innovation to reach our vision to raise the standards of care. From incremental to radical and disruptive we organize with multi-disciplinary experts: our innovation committee.  

What is an innovation?

A new or modified entity that performs or redistributes value(AFNOR, ISO 56000)

The degree of novelty can be expressed by the attributes of an innovation (ISO 56000) :

Incremental innovation : progressive changes (ISO 56000)
Gradual, continuous improvements on existing products, services, processes, … 

Radical innovation: entirely new or significant changes (ISO 56000)​
is at the other end of the value chain compared to incremental innovation​
Ex: technological breakthrough that transform industries – can create new market​

Disruptive innovation: replaces established offers (ISO 56000)​ 

As one of the main actors in the promotion of platelet concentrates preparation, our mission is to understand customers’ needs and provide solutions to help them produce the most qualitative and safe products. Our observation on the platelets’ pooling process led us to the conclusion that platelet concentrates preparation is currently time-consuming, demanding and complex. In order to complete its offer and optimize platelet preparation process, Macopharma has therefore designed Maconnect, the very first multiple sterile connection device

Its one-step procedure
allows up to



The time needed to connect
a pool of Buffy Coat is less than



The very first multiple sterile connection device

Especially designed for pooling operations

Maconnect is a unique and innovative concept, especially designed to optimize, simplify and step up the platelets preparation process, while guaranteeing the preparation of a safe platelet concentrate.

Maconnect is the very first multiple sterile connection device, especially designed for pooling operations.

Its one-step procedure allows the connection of up to 12 tubes.

Connecting one pool of platelets with one single blade and device.

With one Maconnect and one blade, only 30 seconds are needed to connect one pool of Buffy Coat.

The MacoSeal Light is the new innovation by Macopharma, a cordless sealer with an extended battery autonomy, a unique compact lightweight shape and an outstanding intuitive sealing button enabling every usage configuration. 

The remarkable design of the MacoSeal Light was meant to increase the device capabilities while optimising its ergonomics and reducing manual efforts. 

Complete battery charge
Sealings per battery charge

No compromise:

Macopharma bans DEHP, to ensure SAFE and SECURED

blood component solutions to every patient in the world!

Full compliance with REACH regulation

Complete engagement to switch to non-DEHP

More than words, we commit to act and respect our mission:

We support life !

At Macopharma,
we consider Non DEHP
transition as INNOVATION.

Because the value of future bag systems is about safety
we have dedicated a full team of scientific experts to research,
design and develop our new kits as a pure

About REACH regulation

REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) is a regulation of the European Union, adopted to improve the protection of human health and the environment from the risks that can be posed by chemicals.(1)

(1) European Chemicals Agency. Understanding REACH. Available at: https://echa.europa.eu/regulations/reach/understanding-reach Accessed July 2022.

About DEHP

Used for decades, DEHP has a positive effect on the red blood cell membrane integrity and reduces the hemolysis. But the listed toxicological effects have to be considered:(1,2)

Classified as a carcinogenic, mutagenic
or toxic for reproduction (CMR) Ib.

In addition, Endocrine-disrupting effects.

(1) Horowitz B, Stryker MH, Waldman AA, Woods KR, Gass JD, Drago J. Stabilization of red blood cells by the plasticizer, diethylhexylphthalate. Vox Sang 1985; 48:150-5.

(2) AuBuchon JP, Estep TN, Davey RJ. The effect of the plasticizer di-2-ethylhexyl phthalate on the survival of stored RBCs. Blood 1988; 71:448-52. 


* Di(ethylhexyl) terephthalate / phosphate-adenine-glucose-guanosin-saline-mannitol

DEHT has an improved safety profile with no reported mutagenic, carcinogenic or reproductive effects(1,2)

PAGGS-M improves red cell concentrate quality parameters with no reported impact on clinical effectiveness or patient safety(3,4)

DEHT versus DEHP

Improved toxic profile with no mutagenic, carcinogenic or reproductive effects.(1,2)

Associated with lower leaching than DEHP.(5)

Their use is likely to alleviate environmental risks.

Supply risk for DEHP.


Enhanced additive solution that compensates for the impact of haemolysis over time and improves the quality parameters of red cell concentrates (RCC).(3,5)

Used for decades by various entities in Germany.

No reported impact on clinical efficacy and patient safety (DE/CH/AU).(4,6)

(1)Kambia Metabolites 2021; 11:94.

(2)Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on the safety of medical devices containing DEHP plasticised PVC or other plasticisers on neonates and other groups possibly at risk (2015 update). 2017.

(3)Larsson L. Vox Sang. 2021;116:60-70

(4)Flegel WA. Br J Haematol. 2014;165(1):3-16.

(5)Graminske, Transfusion 2018; 58:1100-7.

(6)Hess J. Extended Liquid Storage of Red Blood Cells. In: Manning FJ, Sparacino L, Eds. Blood Donors and the Supply of Blood and Blood Products. Washington DC: The National Academies Press, 1996.